Press Releases for IPXL

Press Releases
Impax Laboratories Continues Trend of Solid Growth in Revenue, Profit and Earnings for the Third Quarter 2009
Impax Laboratories Confirms Patent Challenge Relating to TRICOR® 48mg and 145mg Tablets
Impax Laboratories to Host Third Quarter 2009 Earnings Conference Call and Webcast on November 3
Impax Laboratories Settles Pending Litigation for FLOMAX®
Impax Laboratories Commences Shipment of Generic Adderall XR® Capsules, 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg
Impax Laboratories to Present at the JMP Securities Healthcare Focus Conference
Impax Laboratories Confirms Patent Challenge Relating to ORACEA® Delayed-Release Capsules, 40mg
Impax to Present at the UBS Global Life Sciences Conference
Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinson's Disease
Impax Laboratories Receives Final FDA Approval for Generic Depakote® Extended-Release 500mg Tablets
Impax Laboratories Receives Final FDA Approval for Generic Depakote® Extended-Release 500mg Tablets
Impax Laboratories Reports Second Quarter 2009 Financial Results
InvestorSoup.com Issues Trading Outlook for Labopharm Inc.
Impax to Host Second Quarter 2009 Earnings Conference Call and Webcast on August 4
Impax Laboratories to Be Added to Russell 3000® Index and NASDAQ Biotechnology Equal Weighted Index
Impax Laboratories to be Added to Russell 3000® Index and NASDAQ Biotechnology Equal Weighted Index
Impax Pharmaceuticals Announces Presentation of IPX066 Phase II Data at 13th International Congress of Parkinson's Disease and Movement Disorders
Impax to Present at Upcoming Investor Conferences
Impax Receives FDA Approval for Generic Precose® Tablets, 25 Mg, 50 Mg and 100 Mg
Impax Receives FDA Approval for Generic Precose® Tablets, 25 mg, 50 mg and 100 mg
Impax Laboratories Added to NASDAQ Biotechnology Index
Semi-Annual Changes to the NASDAQ Biotechnology Index
Impax Receives Final FDA Approval for Generic Depakote® Extended-Release 250mg Tablets
Impax to Present at the Bank of America and Merrill Lynch 2009Health Care Conference May 13
Impax to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference May 13
Impax Reports Improved First Quarter 2009 Revenue and Profit
Impax to Host First Quarter 2009 Earnings Conference Call and Webcast on May 5
Impax Pharmaceuticals Reports Positive Achievements on its Two Leading Brand Product Candidates IPX066 and IPX056
NASDAQ OMX Announces First Quarter 2009 New Listings Statistics
Impax Confirms Patent Challenge Relating to Renvela® 800 Mg Tablets
Impax Confirms Patent Challenge Relating to Renvela® 800 mg Tablets
Impax Confirms Patent Lawsuit Relating to Doryx® Tablets 150 Mg
Impax Confirms Patent Lawsuit Relating to Doryx® Tablets 150 mg
Impax Pharmaceuticals to Co-Promote Wyeth's Pristiq®
Impax Pharmaceuticals to Co-Promote Wyeth’s Pristiq®
Impax Confirms ANDA Filing for Doryx® Tablets 150 Mg
Impax Confirms ANDA Filing for Doryx® Tablets 150 mg
Impax Confirms Patent Challenge Relating to RENAGEL® Tablets, 400 mg and 800 mg
IMPAX Common Stock to Begin Trading on NASDAQ
Impax to Present at the Cowen and Company 29th Annual Health Care Conference March 18
Impax to Present at the Barclays Capital Global Healthcare Conference
IMPAX Reports Fourth Quarter and Full Year 2008 Financial Results - Feb 26 2009 8:41AM
IMPAX to Host Fourth Quarter and Full Year 2008 Earnings Conference Call and Webcast on February 26
IMPAX Receives Final FDA Approval for Generic SOLODYN Extended-Release Tablets, 45mg, 90mg and 135mg
IMPAX Receives Final FDA Approval for Omeprazole 40 mg Capsules
IMPAX Laboratories Adopts Shareholder Rights Plan
IMPAX Updates the Filing Status of Its Registration Statement
IMPAX Cancels Scheduled Presentation at UBS Global Specialty Generic Pharmaceuticals Conference
IMPAX Reports on SEC Order Revoking Common Stock Registration and Progress in Obtaining Re-Registration
IMPAX to Present at UBS Global Specialty and Generic Pharmaceuticals Conference
IMPAX to Present at Citi Investment Research 2008 Global Healthcare Conference - Jun 1 2008 11:32PM
IMPAX to Present at Bank of America's 2008 Healthcare Conference - Jun 1 2008 11:31PM
IMPAX Continues to Make Progress in Filing Delinquent Periodic Reports - Jun 1 2008 11:31PM
IMPAX Reports FDA Finding That Budeprion XL(R) 300 mg Is Safe and Effective
IMPAX to Develop Next-Generation Carbidopa/Levodopa Product